
## Joan Montaner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2296697/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multi-ancestry GWAS reveals excitotoxicity associated with outcome after ischaemic stroke. Brain, 2022, 145, 2394-2406.	7.6	15
2	Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic Stroke. Neurotherapeutics, 2022, 19, 513-527.	4.4	2
3	Proteins and pathways in atrial fibrillation and atrial cardiomyopathy underlying cryptogenic stroke. IJC Heart and Vasculature, 2022, 39, 100977.	1.1	0
4	Predicting Atrial Fibrillation with High Risk of Embolization with Atrial Strain and NT-proBNP. Translational Stroke Research, 2021, 12, 735-741.	4.2	25
5	External Validation of Five Scores to Predict Stroke-Associated Pneumonia and the Role of Selected Blood Biomarkers. Stroke, 2021, 52, 325-330.	2.0	22
6	Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome. Stroke, 2021, 52, 132-141.	2.0	36
7	Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer's Disease. Biomedicines, 2021, 9, 72.	3.2	7
8	Blood Biomarkers to Predict Long-Term Mortality after Ischemic Stroke. Life, 2021, 11, 135.	2.4	7
9	Role of Blood-Based Biomarkers in Ischemic Stroke Prognosis. Stroke, 2021, 52, 543-551.	2.0	63
10	Nutraceuticals in the Prevention of Neonatal Hypoxia–Ischemia: A Comprehensive Review of their Neuroprotective Properties, Mechanisms of Action and Future Directions. International Journal of Molecular Sciences, 2021, 22, 2524.	4.1	9
11	Single nucleotide variations in <i>ZBTB46</i> are associated with post-thrombolytic parenchymal haematoma. Brain, 2021, 144, 2416-2426.	7.6	10
12	Genome-wide transcriptome study in skin biopsies reveals an association of E2F4 with cadasil and cognitive impairment. Scientific Reports, 2021, 11, 6846.	3.3	5
13	Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study. European Heart Journal, 2021, 42, 2186-2196.	2.2	40
14	Blood Biomarkers to Differentiate Ischemic and Hemorrhagic Strokes. Neurology, 2021, 96, e1928-e1939.	1.1	34
15	D-Dimer as Predictor of Large Vessel Occlusion in Acute Ischemic Stroke. Stroke, 2021, 52, 852-858.	2.0	25
16	Blood Biomarker Panels for the Early Prediction of Strokeâ€Associated Complications. Journal of the American Heart Association, 2021, 10, e018946.	3.7	17
17	Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage. Journal of Clinical Medicine, 2021, 10, 989.	2.4	5
18	SARS-CoV-2 and Stroke Characteristics. Stroke, 2021, 52, e117-e130.	2.0	51

#	Article	IF	CITATIONS
19	Integrative Multi-omics Analysis to Characterize Human Brain Ischemia. Molecular Neurobiology, 2021, 58, 4107-4121.	4.0	12
20	Angiogenin in the Neurogenic Subventricular Zone After Stroke. Frontiers in Neurology, 2021, 12, 662235.	2.4	5
21	RP11-362K2.2:RP11-767I20.1 Genetic Variation Is Associated with Post-Reperfusion Therapy Parenchymal Hematoma. A GWAS Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 3137.	2.4	6
22	Role of microglial and endothelial CD36 in post-ischemic inflammasome activation and interleukin-11 <sup>2</sup> -induced endothelial activation. Brain, Behavior, and Immunity, 2021, 95, 489-501.	4.1	17
23	Causal Effect of MMP-1 (Matrix Metalloproteinase-1), MMP-8, and MMP-12 Levels on Ischemic Stroke. Stroke, 2021, 52, e316-e320.	2.0	18
24	Clinical Outcomes of Mechanical Thrombectomy in Stroke Tandem Lesions According to Intracranial Occlusion Location. Journal of Stroke, 2021, 23, 124-127.	3.2	6
25	Peripheral inflammation preceeding ischemia impairs neuronal survival through mechanisms involving miRâ€127 in aged animals. Aging Cell, 2021, 20, e13287.	6.7	7
26	Cardioembolic Ischemic Stroke Gene Expression Fingerprint in Blood: a Systematic Review and Verification Analysis. Translational Stroke Research, 2020, 11, 326-336.	4.2	14
27	Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 203-210.	3.0	69
28	Correlation of blood biomarkers with early-onset seizures after an acute stroke event. Epilepsy and Behavior, 2020, 104, 106549.	1.7	17
29	Circulating Aquaporin-4 as A biomarker of early neurological improvement in stroke patients: A pilot study. Neuroscience Letters, 2020, 714, 134580.	2.1	7
30	Circulating microRNA after autologous bone marrow mononuclear cell (BM-MNC) injection in patients with ischemic stroke. Journal of Investigative Medicine, 2020, 68, 807-810.	1.6	4
31	Blood-based biomarkers and stem cell therapy in human stroke: a systematic review. Molecular Biology Reports, 2020, 47, 6247-6258.	2.3	3
32	Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank Samples. Frontiers in Neurology, 2020, 11, 589628.	2.4	4
33	<p>Risk of Atrial Fibrillation, Ischemic Stroke and Cognitive Impairment: Study of a Population Cohort a‰¥65 Years of Age</p> . Vascular Health and Risk Management, 2020, Volume 16, 445-454.	2.3	4
34	Blood biomarkers for the diagnosis and differentiation of stroke: A systematic review and meta-analysis. International Journal of Stroke, 2020, 15, 704-721.	5.9	28
35	A Mouse Brain-based Multi-omics Integrative Approach Reveals Potential Blood Biomarkers for Ischemic Stroke. Molecular and Cellular Proteomics, 2020, 19, 1921-1936.	3.8	20
36	Lessons learned from proteome analysis of perinatal neurovascular pathologies. Expert Review of Proteomics, 2020, 17, 469-481.	3.0	1

#	Article	IF	CITATIONS
37	Blood biomarkers predictive of epilepsy after an acute stroke event. Epilepsia, 2020, 61, 2244-2253.	5.1	27
38	TNF-R1 Correlates with Cerebral Perfusion and Acute Ischemia Following Subarachnoid Hemorrhage. Neurocritical Care, 2020, 33, 679-687.	2.4	11
39	SAA (Serum Amyloid A). Stroke, 2020, 51, 3523-3530.	2.0	16
40	Prevalence and risk factors of silent brain infarcts in patients with AF detected by 3T-MRI. Journal of Neurology, 2020, 267, 2675-2682.	3.6	5
41	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clinical Pharmacology and Therapeutics, 2020, 108, 1067-1077.	4.7	32
42	Cervical dissection diagnoses increase following endovascular treatments. Journal of International Medical Research, 2020, 48, 030006052090674.	1.0	0
43	Break in the Stroke Chain of Survival due to COVID-19. Stroke, 2020, 51, 2307-2314.	2.0	125
44	Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis. Journal of Neurology, 2020, 267, 3021-3037.	3.6	16
45	Cold stress protein RBM3 responds to hypothermia and is associated with good stroke outcome. Brain Communications, 2020, 2, fcaa078.	3.3	15
46	Identification of 20 novel loci associated with ischaemic stroke. Epigenome-wide association study. Epigenetics, 2020, 15, 988-997.	2.7	22
47	Natalizumab in acute ischemic stroke (ACTION II). Neurology, 2020, 95, e1091-e1104.	1.1	55
48	Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage. Scientific Reports, 2020, 10, 10329.	3.3	5
49	Usefulness of TNFR1 as biomarker of intracranial aneurysm in patients with spontaneous subarachnoid hemorrhage. Future Science OA, 2020, 6, FSO431.	1.9	6
50	Genome-Wide Association Study of VKORC1 and CYP2C9 on acenocoumarol dose, stroke recurrence and intracranial haemorrhage in Spain. Scientific Reports, 2020, 10, 2806.	3.3	7
51	Recommendations for Clinical Trials in ICH. Stroke, 2020, 51, 1333-1338.	2.0	42
52	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 73, 1585-1595.	2.6	25
53	Inflammatory and stress markers predicting pneumonia, outcome, and etiology in patients with stroke. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	25
54	Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nature Reviews Neurology, 2020, 16, 247-264.	10.1	167

#	Article	IF	CITATIONS
55	Characterization of a CholesteroNitrone (ISQ-201), a Novel Drug Candidate for the Treatment of Ischemic Stroke. Antioxidants, 2020, 9, 291.	5.1	9
56	Discriminative value of glial fibrillar acidic protein (GFAP) as a diagnostic tool in acute stroke. Individual patient data meta-analysis. Journal of Investigative Medicine, 2020, 68, 1379-1385.	1.6	10
57	DNA methylation of MMPs and TIMPs in atherothrombosis process in carotid plaques and blood tissues. Oncotarget, 2020, 11, 905-912.	1.8	4
58	The Value of Transcranial Doppler Sonography in Hyperperfusion Syndrome after Carotid Artery Stenting: A Nationwide Prospective Study. Journal of Stroke, 2020, 22, 254-257.	3.2	3
59	Nighttime hypoxia affects global cognition, memory, and executive function in community-dwelling individuals with hypertension. Journal of Clinical Sleep Medicine, 2020, 16, 243-250.	2.6	3
60	Sex Differences by Hospital-Level in Performance and Outcomes of Endovascular Treatment for Acute Ischemic Stroke. Journal of Stroke, 2020, 22, 258-261.	3.2	9
61	Validation of a clinical-genetics score to predict hemorrhagic transformations after rtPA. Neurology, 2019, 93, e851-e863.	1.1	10
62	Paper microfluidics on screen-printed electrodes for simple electrochemical magneto-immunosensor performance. Sensors and Actuators B: Chemical, 2019, 298, 126897.	7.8	13
63	Biomarkers predictive value for early diagnosis of Strokeâ€Associated Pneumonia. Annals of Clinical and Translational Neurology, 2019, 6, 1882-1887.	3.7	12
64	Comments on: "Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels as a Biomarker of Acute Intracerebral Hemorrhage― Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 2585-2586.	1.6	0
65	Genome-Wide Association Study of White Blood Cell Counts in Patients With Ischemic Stroke. Stroke, 2019, 50, 3618-3621.	2.0	13
66	Application of an Aptamer-Based Proteomics Assay (SOMAscanâ,,¢) in Rat Cerebrospinal Fluid. Methods in Molecular Biology, 2019, 2044, 221-231.	0.9	2
67	Venous and arterial TNF-R1 predicts outcome and complications in acute subarachnoid hemorrhage. Neurocritical Care, 2019, 31, 107-115.	2.4	6
68	New Quinolylnitrones for Stroke Therapy: Antioxidant and Neuroprotective ( <i>Z</i> )- <i>N</i> - <i>tert</i> -Butyl-1-(2-chloro-6-methoxyquinolin-3-yl)methanimine Oxide as a New Lead-Compound for Ischemic Stroke Treatment. Journal of Medicinal Chemistry, 2019, 62, 2184-2201.	6.4	35
69	Diagnostic accuracy of noncontrast CT imaging markers in cerebral venous thrombosis. Neurology, 2019, 92, e841-e851.	1.1	22
70	Neuroprotective Effects of Diets Containing Olive Oil and DHA/EPA in a Mouse Model of Cerebral Ischemia. Nutrients, 2019, 11, 1109.	4.1	27
71	Matrix metalloproteinases and ADAMs in stroke. Cellular and Molecular Life Sciences, 2019, 76, 3117-3140.	5.4	43
72	Antibiotic treatment for pneumonia complicating stroke: Recommendations from the pneumonia in stroke consensus (PISCES) group. European Stroke Journal, 2019, 4, 318-328.	5.5	22

#	Article	IF	CITATIONS
73	Antibiotic Class and Outcome in Post-stroke Infections: An Individual Participant Data Pooled Analysis of VISTA-Acute. Frontiers in Neurology, 2019, 10, 504.	2.4	17
74	Clinical Predictors of Hyperperfusion Syndrome Following Carotid Stenting. JACC: Cardiovascular Interventions, 2019, 12, 873-882.	2.9	17
75	Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice. Alzheimer's Research and Therapy, 2019, 11, 42.	6.2	29
76	Overlap in the Genetic Architecture of Stroke Risk, Early Neurological Changes, and Cardiovascular Risk Factors. Stroke, 2019, 50, 1339-1345.	2.0	17
77	Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial. European Stroke Journal, 2019, 4, 254-262.	5.5	48
78	Association of Apolipoprotein E With Intracerebral Hemorrhage Risk by Race/Ethnicity. JAMA Neurology, 2019, 76, 480.	9.0	43
79	Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study. BMJ Open Diabetes Research and Care, 2019, 7, e000845.	2.8	24
80	Searching for Atrial Fibrillation Poststroke. Circulation, 2019, 140, 1834-1850.	1.6	184
81	N-Terminal Pro B-Type Natriuretic Peptide's Usefulness for Paroxysmal Atrial Fibrillation Detection Among Populations Carrying Cardiovascular Risk Factors. Frontiers in Neurology, 2019, 10, 1226.	2.4	10
82	Cognitive Impact of Cerebral Small Vessel Disease Changes in Patients With Hypertension. Hypertension, 2019, 73, 342-349.	2.7	55
83	<i>PATJ</i> Low Frequency Variants Are Associated With Worse Ischemic Stroke Functional Outcome. Circulation Research, 2019, 124, 114-120.	4.5	49
84	Glial fibrillary acidic protein for the early diagnosis of intracerebral hemorrhage: Systematic review and meta-analysis of diagnostic test accuracy. International Journal of Stroke, 2019, 14, 390-399.	5.9	31
85	Chest Computed Tomography Findings and Validation of Clinical Criteria of Stroke Associated Pneumonia. Journal of Stroke, 2019, 21, 217-219.	3.2	6
86	Clinical Variables and Genetic Risk Factors Associated with the Acute Outcome of Ischemic Stroke: A Systematic Review. Journal of Stroke, 2019, 21, 276-289.	3.2	27
87	Mediterranean Diet and Physical Activity Protect from Silent Brain Infarcts in a Cohort of Patients with Atrial Fibrillation. Journal of Stroke, 2019, 21, 353-355.	3.2	4
88	Endothelial Progenitor Cell Secretome and Oligovascular Repair in a Mouse Model of Prolonged Cerebral Hypoperfusion. Stroke, 2018, 49, 1003-1010.	2.0	66
89	Arterial Stiffness Is Associated With Basal Ganglia Enlarged Perivascular Spaces and Cerebral Small Vessel Disease Load. Stroke, 2018, 49, 1279-1281.	2.0	61
90	Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke. Neurology, 2018, 90, e995-e1004.	1.1	48

#	Article	IF	CITATIONS
91	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159.	2.7	24
92	Obstructive sleep apnea and silent cerebral infarction in hypertensive individuals. Journal of Sleep Research, 2018, 27, 232-239.	3.2	22
93	Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 542-553.	3.8	10
94	External Validation of the ISAN, A2DS2, and AIS-APS Scores for Predicting Stroke-Associated Pneumonia. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 673-676.	1.6	26
95	Yield of atrial fibrillation detection with Textile Wearable Holter from the acute phase of stroke: Pilot study of Crypto-AF registry. International Journal of Cardiology, 2018, 251, 45-50.	1.7	46
96	Using magnetic beads and signal amplifiers to produce short and simple immunoassays: Application to MMP-9 detection in plasma samples. Analytica Chimica Acta, 2018, 999, 144-154.	5.4	31
97	Single Cell Immuno-Laser Microdissection Coupled to Label-Free Proteomics to Reveal the Proteotypes of Human Brain Cells After Ischemia. Molecular and Cellular Proteomics, 2018, 17, 175-189.	3.8	26
98	Author response: Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke. Neurology, 2018, 91, 899-899.	1.1	1
99	Safety of Early Carotid Artery Stenting for Symptomatic Stenosis in Daily Practice. European Journal of Vascular and Endovascular Surgery, 2018, 56, 776-782.	1.5	4
100	Protective Effects of Endothelial Progenitor Cell-Derived Extracellular Mitochondria in Brain Endothelium. Stem Cells, 2018, 36, 1404-1410.	3.2	106
101	Importance of Angiogenin and Endothelial Progenitor Cells After Rehabilitation Both in Ischemic Stroke Patients and in a Mouse Model of Cerebral Ischemia. Frontiers in Neurology, 2018, 9, 508.	2.4	20
102	Combining H-FABP and GFAP increases the capacity to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury. PLoS ONE, 2018, 13, e0200394.	2.5	33
103	Detection of plasma MMP-9 within minutes. Unveiling some of the clues to develop fast and simple electrochemical magneto-immunosensors. Biosensors and Bioelectronics, 2018, 115, 45-52.	10.1	32
104	Using polyHRP to produce simplified immunoassays and electrochemical immunosensors. Application to MMP-9 detection in plasma and uterine aspirates. Sensors and Actuators B: Chemical, 2018, 269, 377-384.	7.8	14
105	Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878934.	3.5	77
106	Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Lancet Neurology, The, 2018, 17, 885-894.	10.2	229
107	Early measurement of interleukin-10 predicts the absence of CT scan lesions in mild traumatic brain injury. PLoS ONE, 2018, 13, e0193278.	2.5	39
108	<i>17p12</i> Influences Hematoma Volume and Outcome in Spontaneous Intracerebral Hemorrhage. Stroke, 2018, 49, 1618-1625.	2.0	26

Joan Montaner

#	Article	IF	CITATIONS
109	Microbiological Etiologies of Pneumonia Complicating Stroke. Stroke, 2018, 49, 1602-1609.	2.0	31
110	Neuroprotective diets for stroke. Neurochemistry International, 2017, 107, 4-10.	3.8	26
111	Blood markers of inflammation and endothelial dysfunction in cardioembolic stroke: systematic review and meta-analysis. Biomarkers, 2017, 22, 200-209.	1.9	26
112	Câ€reactive protein in the detection of postâ€stroke infections: systematic review and individual participant data analysis. Journal of Neurochemistry, 2017, 141, 305-314.	3.9	23
113	Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology, The, 2017, 16, 217-226.	10.2	176
114	GRECOS Project (Genotyping Recurrence Risk of Stroke). Stroke, 2017, 48, 1147-1153.	2.0	23
115	New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator. Cardiovascular Research, 2017, 113, 1219-1229.	3.8	15
116	Principles of precision medicine in stroke. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 54-61.	1.9	64
117	<i>COL4A2</i> is associated with lacunar ischemic stroke and deep ICH. Neurology, 2017, 89, 1829-1839.	1.1	58
118	Sepsis biomarkers reprofiling to predict stroke-associated infections. Journal of Neuroimmunology, 2017, 312, 19-23.	2.3	16
119	Intravenous treatment with human recombinant ApoA-I Milano reduces beta amyloid cerebral deposition in the APP23-transgenic mouse model of Alzheimer's disease. Neurobiology of Aging, 2017, 60, 116-128.	3.1	29
120	Blood Biomarkers for the Early Diagnosis of Stroke. Stroke, 2017, 48, 2419-2425.	2.0	107
121	Quinolinyl Nitrone RP19 Induces Neuroprotection after Transient Brain Ischemia. ACS Chemical Neuroscience, 2017, 8, 2202-2213.	3.5	23
122	Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds. Neurology, 2017, 89, 820-829.	1.1	180
123	The choroid plexus is a key cerebral invasion route for T cells after stroke. Acta Neuropathologica, 2017, 134, 851-868.	7.7	87
124	Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β-amyloidosis. Scientific Reports, 2017, 7, 14637.	3.3	31
125	Stroke-induced immunodepression and dysphagia independently predict stroke-associated pneumonia – The PREDICT study. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3671-3682.	4.3	133
126	Profiling and identification of new proteins involved in brain ischemia using MALDI-imaging-mass-spectrometry. Journal of Proteomics, 2017, 152, 243-253.	2.4	23

Joan Montaner

#	Article	IF	CITATIONS
127	Genetic variants influencing elevated myeloperoxidase levels increase risk of stroke. Brain, 2017, 140, 2663-2672.	7.6	12
128	The impact of post-stroke complications on in-hospital mortality depends on stroke severity. European Stroke Journal, 2017, 2, 54-63.	5.5	24
129	Systematic Review of Cysteine-Sparing NOTCH3 Missense Mutations in Patients with Clinical Suspicion of CADASIL. International Journal of Molecular Sciences, 2017, 18, 1964.	4.1	62
130	The Randomized Controlled STRAWINSKI Trial: Procalcitonin-Guided Antibiotic Therapy after Stroke. Frontiers in Neurology, 2017, 8, 153.	2.4	36
131	H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury. PLoS ONE, 2017, 12, e0175572.	2.5	34
132	Selection bias in clinical stroke trials depending on ability to consent. BMC Neurology, 2017, 17, 206.	1.8	18
133	Nano-zymography Using Laser-Scanning Confocal Microscopy Unmasks Proteolytic Activity of Cell-Derived Microparticles. Theranostics, 2016, 6, 610-626.	10.0	12
134	Increasing Dose of Autologous Bone Marrow Mononuclear Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis of Two Clinical Trials. Stem Cells International, 2016, 2016, 1-8.	2.5	27
135	Exome Sequencing and Clot Lysis Experiments Demonstrate the R458C Mutation of the Alpha Chain of Fibrinogen to be Associated with Impaired Fibrinolysis in a Family with Thrombophilia. Journal of Atherosclerosis and Thrombosis, 2016, 23, 431-440.	2.0	6
136	Rehabilitation Profiles of Older Adult Stroke Survivors Admitted to Intermediate Care Units: A Multi-Centre Study. PLoS ONE, 2016, 11, e0166304.	2.5	16
137	Whole exome sequencing analysis reveals TRPV3 as a risk factor for cardioembolic stroke/subtitle. Thrombosis and Haemostasis, 2016, 116, 1165-1771.	3.4	6
138	Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats. International Journal of Nanomedicine, 2016, Volume 11, 3035-3048.	6.7	56
139	Antiâ€inflammatory effects of ADAMTSâ€4 in a mouse model of ischemic stroke. Glia, 2016, 64, 1492-1507.	4.9	35
140	Circulating cell-free DNA is a predictor of short-term neurological outcome in stroke patients treated with intravenous thrombolysis. Journal of Circulating Biomarkers, 2016, 5, 184945441666879.	1.3	25
141	Modulation of Amyloid-β1–40 Transport by ApoA1 and ApoJ Across an in vitro Model of the Blood-Brain Barrier. Journal of Alzheimer's Disease, 2016, 53, 677-691.	2.6	45
142	Hyperfibrinolysis increases blood–brain barrier permeability by a plasmin- and bradykinin-dependent mechanism. Blood, 2016, 128, 2423-2434.	1.4	104
143	Microalbuminuria and the Combination of MRI Markers of Cerebral Small Vessel Disease. Cerebrovascular Diseases, 2016, 42, 66-72.	1.7	17
144	<i>TRAF3</i> Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke. Stroke, 2016, 47, 1180-1186.	2.0	46

#	Article	IF	CITATIONS
145	Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2016, 15, 695-707.	10.2	130
146	Factor seven activating protease (FSAP) predicts response to intravenous thrombolysis in acute ischemic stroke. International Journal of Stroke, 2016, 11, 646-655.	5.9	13
147	Dementia Rating Scale-2 normative data for middle-and older-aged Castilian speaking Spaniards. Clinical Neuropsychologist, 2016, 30, 1443-1456.	2.3	5
148	Plasma Matrix Metalloproteinases in Patients With Stroke During Intensive Rehabilitation Therapy. Archives of Physical Medicine and Rehabilitation, 2016, 97, 1832-1840.	0.9	17
149	Automated quantification of cerebral edema following hemispheric infarction: Application of a machine-learning algorithm to evaluate CSF shifts on serial head CTs. NeuroImage: Clinical, 2016, 12, 673-680.	2.7	49
150	Combination of Thrombolysis and Statins in Acute Stroke Is Safe. Stroke, 2016, 47, 2870-2873.	2.0	58
151	Natalizumab: a new therapy for acute ischemic stroke?. Expert Review of Neurotherapeutics, 2016, 16, 1013-1021.	2.8	13
152	Blood/Brain Biomarkers of Inflammation After Stroke and Their Association With Outcome: From C-Reactive Protein to Damage-Associated Molecular Patterns. Neurotherapeutics, 2016, 13, 671-684.	4.4	78
153	Galectin-3 is not an outcome biomarker in ischemic stroke. Letter concerning the study â€~Role of galectin-3 in plasma as a predictive biomarker of outcome after acute intracerebral hemorrhage. Journal of the Neurological Sciences, 2016, 371, 67-68.	0.6	5
154	Admission troponin-I predicts subsequent cardiac complications and mortality in acute stroke patients. European Stroke Journal, 2016, 1, 205-212.	5.5	11
155	Genetic variants inCETPincrease risk of intracerebral hemorrhage. Annals of Neurology, 2016, 80, 730-740.	5.3	33
156	Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome. Cerebrovascular Diseases, 2016, 42, 404-414.	1.7	16
157	N-terminal pro-brain natriuretic peptide and subclinical brain small vessel disease. Neurology, 2016, 87, 2533-2539.	1.1	18
158	Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to lytic therapy. Thrombosis and Haemostasis, 2016, 115, 1129-1137.	3.4	31
159	Plasmatic retinolâ€binding protein 4 and glial fibrillary acidic protein as biomarkers to differentiate ischemic stroke and intracerebral hemorrhage. Journal of Neurochemistry, 2016, 136, 416-424.	3.9	49
160	Clinical risk scores for predicting stroke-associated pneumonia: A systematic review. European Stroke Journal, 2016, 1, 76-84.	5.5	39
161	Predictors of Restenosis Following Carotid Angioplasty and Stenting. Stroke, 2016, 47, 2144-2147.	2.0	35
162	<i>PPM1A</i> Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients. Stroke, 2016, 47, 1926-1929.	2.0	28

#	Article	IF	CITATIONS
163	High daytime and nighttime ambulatory pulse pressure predict poor cognitive function and mild cognitive impairment in hypertensive individuals. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 253-263.	4.3	14
164	Matrix metalloproteinase-13 participates in neuroprotection and neurorepair after cerebral ischemia in mice. Neurobiology of Disease, 2016, 91, 236-246.	4.4	25
165	Identification of Plasma Biomarkers of Human Intracerebral Hemorrhage Subtypes through Microarray Technology. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 665-671.	1.6	4
166	Characterization of secretomes from a human blood brain barrier endothelial cells in-vitro model after ischemia by stable isotope labeling with aminoacids in cell culture (SILAC). Journal of Proteomics, 2016, 133, 100-112.	2.4	17
167	Ischemic stroke outcome: A review of the influence of post-stroke complications within the different scenarios of stroke care. European Journal of Internal Medicine, 2016, 29, 9-21.	2.2	94
168	ApoA1, ApoJ and ApoE Plasma Levels and Genotype Frequencies in Cerebral Amyloid Angiopathy. NeuroMolecular Medicine, 2016, 18, 99-108.	3.4	20
169	Neuroinflammatory biomarkers: From stroke diagnosis and prognosis to therapy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 411-424.	3.8	79
170	Consensus statement for diagnosis of subcortical small vessel disease. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 6-25.	4.3	173
171	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. Journal of Alzheimer's Disease, 2015, 48, 711-720.	2.6	71
172	DNA methylation levels are highly correlated between pooled samples and averaged values when analysed using the Infinium HumanMethylation450 BeadChip array. Clinical Epigenetics, 2015, 7, 78.	4.1	17
173	An Inflammatory Polymorphisms Risk Scoring System for the Differentiation of Ischemic Stroke Subtypes. Mediators of Inflammation, 2015, 2015, 1-7.	3.0	9
174	Nâ€glycome Profile Levels Relate to Silent Brain Infarcts in a Cohort of Hypertensives. Journal of the American Heart Association, 2015, 4, .	3.7	3
175	Lysophosphatidylcholine to stratify risk of ischemic stroke in TIA. Neurology, 2015, 84, 17-18.	1.1	6
176	Common variation in <i>COL4A1/COL4A2</i> is associated with sporadic cerebral small vessel disease. Neurology, 2015, 84, 918-926.	1.1	106
177	The post-stroke clotting battle: ADAMTS13 falls and puts out of control vWF into brain arteries. Journal of the Neurological Sciences, 2015, 348, 1-2.	0.6	3
178	Endothelial progenitor cells and revascularization following stroke. Brain Research, 2015, 1623, 150-159.	2.2	44
179	Cerebral Amyloid Angiopathy-Related Atraumatic Convexal Subarachnoid Hemorrhage: An ARIA before the Tsunami. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 710-717.	4.3	39
180	Impaired Vascular Remodeling after Endothelial Progenitor Cell Transplantation in MMP9-Deficient Mice Suffering Cortical Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1547-1551.	4.3	31

#	Article	IF	CITATIONS
181	Immunomodulation by interleukin-33 is protective in stroke through modulation of inflammation. Brain, Behavior, and Immunity, 2015, 49, 322-336.	4.1	107
182	Diagnosis of Stroke-Associated Pneumonia. Stroke, 2015, 46, 2335-2340.	2.0	275
183	Sequential Amyloid-β Degradation by the Matrix Metalloproteases MMP-2 and MMP-9. Journal of Biological Chemistry, 2015, 290, 15078-15091.	3.4	107
184	Advanced neuroprotection for brain ischemia: an alternative approach to minimize stroke damage. Expert Opinion on Investigational Drugs, 2015, 24, 1137-1142.	4.1	16
185	Short-Term Blood Pressure Variability Relates to the Presence of Subclinical Brain Small Vessel Disease in Primary Hypertension. Hypertension, 2015, 66, 634-640.	2.7	72
186	Platelet function testing in transient ischaemic attack and ischaemic stroke: A comprehensive systematic review of the literature. Platelets, 2015, 26, 402-412.	2.3	44
187	Molecular damage in <scp>F</scp> abry disease: Characterization and prediction of alphaâ€galactosidase <scp>A</scp> pathological mutations. Proteins: Structure, Function and Bioinformatics, 2015, 83, 91-104.	2.6	23
188	B-Type Natriuretic Peptides Help in Cardioembolic Stroke Diagnosis. Stroke, 2015, 46, 1187-1195.	2.0	132
189	How Is Pneumonia Diagnosed in Clinical Stroke Research?. Stroke, 2015, 46, 1202-1209.	2.0	124
190	Intra-Arterial Bone Marrow Mononuclear Cells (BM-MNCS) Transplantation in Acute Ischemic Stroke (IBiS Trial): Protocol of a Phase II, Randomized, Dose-Finding, Controlled Multicenter Trial. International Journal of Stroke, 2015, 10, 1149-1152.	5.9	43
191	CholesteroNitrones for Stroke. Journal of Medicinal Chemistry, 2015, 58, 6704-6709.	6.4	26
192	Monitoring of Cortical Activity Postreperfusion. A Powerful Tool for Predicting Clinical Response Immediately After Recanalization. Journal of Neuroimaging, 2015, 25, 257-262.	2.0	5
193	STAT-Dependent Upregulation of 12/15-Lipoxygenase Contributes to Neuronal Injury after Stroke. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 2043-2051.	4.3	40
194	Recommendations From the International Stroke Genetics Consortium, Part 1. Stroke, 2015, 46, 279-284.	2.0	22
195	NURR1 Involvement in Recombinant Tissue-Type Plasminogen Activator Treatment Complications After Ischemic Stroke. Stroke, 2015, 46, 477-484.	2.0	14
196	Global DNA Methylation of Ischemic Stroke Subtypes. PLoS ONE, 2014, 9, e96543.	2.5	46
197	Cardioembolic Stroke Diagnosis Using Blood Biomarkers. Current Cardiology Reviews, 2014, 9, 340-352.	1.5	22
198	Prevalence and Associated Factors of Silent Brain Infarcts in a Mediterranean Cohort of Hypertensives. Hypertension, 2014, 64, 658-663.	2.7	30

#	Article	IF	CITATIONS
199	Role of betaâ€defensin 2 and interleukinâ€4 receptor as stroke outcome biomarkers. Journal of Neurochemistry, 2014, 129, 463-472.	3.9	15
200	Prognostic Value of Plasma Chitotriosidase Activity in Acute Stroke Patients. International Journal of Stroke, 2014, 9, 910-916.	5.9	10
201	Neuroendocrine hormones as prognostic biomarkers in the setting of acute stroke: overcoming the major hurdles. Expert Review of Neurotherapeutics, 2014, 14, 1391-1403.	2.8	14
202	Potential Role of Blood Biomarkers in the Management of Nontraumatic Intracerebral Hemorrhage. Cerebrovascular Diseases, 2014, 38, 395-409.	1.7	59
203	B-type natriuretic peptides and mortality after stroke: A systematic review and meta-analysis. Neurology, 2014, 83, 292-293.	1.1	4
204	Fluorescent Molecular Peroxidation Products. Stroke, 2014, 45, 432-437.	2.0	10
205	Neuronal Production of Lipocalin-2 as a Help-Me Signal for Glial Activation. Stroke, 2014, 45, 2085-2092.	2.0	117
206	In vitro angiogenic performance and in vivo brain targeting of magnetized endothelial progenitor cells for neurorepair therapies. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 225-234.	3.3	53
207	Rapid synthesis of water-dispersible superparamagnetic iron oxide nanoparticles by a microwave-assisted route for safe labeling of endothelial progenitor cells. Acta Biomaterialia, 2014, 10, 3775-3785.	8.3	57
208	Mild hypothermia protects against oxygen glucose deprivation (OGD)-induced cell death in brain slices from adult mice. Journal of Neural Transmission, 2014, 121, 113-117.	2.8	5
209	Role of lipoprotein-associated phospholipase A2 activity for the prediction of silent brain infarcts in women. Atherosclerosis, 2014, 237, 811-815.	0.8	10
210	Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: A systematic review and meta-analysis. Journal of Neuroimmunology, 2014, 274, 215-224.	2.3	100
211	European Stroke Organisation (ESO) Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. International Journal of Stroke, 2014, 9, 840-855.	5.9	638
212	Meta-analysis in more than 17,900 cases of ischemic stroke reveals a novel association at 12q24.12. Neurology, 2014, 83, 678-685.	1.1	89
213	EuroHYP-1: European Multicenter, Randomized, Phase III Clinical Trial of Therapeutic Hypothermia plus Best Medical Treatment vs. Best Medical Treatment Alone for Acute Ischemic Stroke. International Journal of Stroke, 2014, 9, 642-645.	5.9	118
214	Brain proteomics identifies potential simvastatin targets in acute phase of stroke in a rat embolic model. Journal of Neurochemistry, 2014, 130, 301-312.	3.9	25
215	Antiplatelet effects of clopidogrel dose adjustment (75Âmg/d vs 150Âmg/d) after carotid stenting. Journal of Vascular Surgery, 2014, 60, 428-435.	1.1	12
216	Meta-analysis of Genome-wide Association Studies Identifies 1q22 as a Susceptibility Locus for Intracerebral Hemorrhage. American Journal of Human Genetics, 2014, 94, 511-521.	6.2	235

#	Article	IF	CITATIONS
217	Developing biomarkers for cerebral amyloid angiopathy trials: do potential disease phenotypes hold promise? – Authors' reply. Lancet Neurology, The, 2014, 13, 540.	10.2	1
218	Outcome markers for clinical trials in cerebral amyloid angiopathy. Lancet Neurology, The, 2014, 13, 419-428.	10.2	124
219	Intra-Arterial Bone Marrow Mononuclear Cell Transplantation Correlates with GM-CSF, PDGF-BB, and MMP-2 Serum Levels in Stroke Patients: Results from a Clinical Trial. Cell Transplantation, 2014, 23, 57-64.	2.5	35
220	Rat Middle Cerebral Artery Occlusion Is Not a Suitable Model for the Study of Stroke-Induced Spontaneous Infections. PLoS ONE, 2014, 9, e99169.	2.5	2
221	Arterial Blood Gas Analysis of Samples Directly Obtained Beyond Cerebral Arterial Occlusion During Endovascular Procedures Predicts Clinical Outcome. Journal of Neuroimaging, 2013, 23, 180-184.	2.0	7
222	Distal Occlusion of the Middle Cerebral Artery in Mice: Are We Ready to Assess Long-Term Functional Outcome?. Translational Stroke Research, 2013, 4, 297-307.	4.2	55
223	The angiogenic gene profile of circulating endothelial progenitor cells from ischemic stroke patients. Vascular Cell, 2013, 5, 3.	0.2	18
224	Investigating silent strokes in hypertensives: a magnetic resonance imaging study (ISSYS): rationale and protocol design. BMC Neurology, 2013, 13, 130.	1.8	41
225	Blood biomarkers for predicting outcome after stroke. Neurology, 2013, 80, 1270-1271.	1.1	1
226	From brain to blood: New biomarkers for ischemic stroke prognosis. Journal of Proteomics, 2013, 94, 138-148.	2.4	28
227	ADAMTS proteoglycanases in the physiological and pathological central nervous system. Journal of Neuroinflammation, 2013, 10, 133.	7.2	77
228	Statin Therapy Should Not be Discontinued in Patients With Intracerebral Hemorrhage. Stroke, 2013, 44, 2060-2061.	2.0	12
229	Common Variants Within Oxidative Phosphorylation Genes Influence Risk of Ischemic Stroke and Intracerebral Hemorrhage. Stroke, 2013, 44, 612-619.	2.0	33
230	Heritability Estimates Identify a Substantial Genetic Contribution to Risk and Outcome of Intracerebral Hemorrhage. Stroke, 2013, 44, 1578-1583.	2.0	88
231	Letter by Riba-Llena et al Regarding Article, "Not Listened or Not Reported Rather Than Silent Strokeâ€. Stroke, 2013, 44, e42.	2.0	1
232	B-type natriuretic peptides and mortality after stroke. Neurology, 2013, 81, 1976-1985.	1.1	82
233	Immunological Biomarkers Improve the Accuracy of Clinical Risk Models of Infection in the Acute Phase of Ischemic Stroke. Cerebrovascular Diseases, 2013, 35, 220-227.	1.7	15
234	Cerebral ischaemia and matrix metalloproteinaseâ€9 modulate the angiogenic function of early and late outgrowth endothelial progenitor cells. Journal of Cellular and Molecular Medicine, 2013, 17, 1543-1553.	3.6	34

#	Article	IF	CITATIONS
235	Combining Statins with Tissue Plasminogen Activator Treatment After Experimental and Human Stroke: A Safety Study on Hemorrhagic Transformation. CNS Neuroscience and Therapeutics, 2013, 19, 863-870.	3.9	10
236	Inhibition of 12/15â€lipoxygenase as therapeutic strategy to treat stroke. Annals of Neurology, 2013, 73, 129-135.	5.3	96
237	Genes involved in hemorrhagic transformations that follow recombinant t-PA treatment in stroke patients. Pharmacogenomics, 2013, 14, 495-504.	1.3	18
238	Statin Therapy and Outcome After Ischemic Stroke. Stroke, 2013, 44, 448-456.	2.0	200
239	DNA Isolation Method Is a Source of Global DNA Methylation Variability Measured with LUMA. Experimental Analysis and a Systematic Review. PLoS ONE, 2013, 8, e60750.	2.5	24
240	Factors Secreted by Endothelial Progenitor Cells Enhance Neurorepair Responses after Cerebral Ischemia in Mice. PLoS ONE, 2013, 8, e73244.	2.5	93
241	Targeting p35/Cdk5 Signalling via CIP-Peptide Promotes Angiogenesis in Hypoxia. PLoS ONE, 2013, 8, e75538.	2.5	17
242	Burden of Risk Alleles for Hypertension Increases Risk of Intracerebral Hemorrhage. Stroke, 2012, 43, 2877-2883.	2.0	39
243	Predictors of Tissue-Type Plasminogen Activator Nonresponders According to Location of Vessel Occlusion. Stroke, 2012, 43, 417-421.	2.0	31
244	Lipoprotein-Associated Phospholipase A <sub>2</sub> Activity Is Associated with Large-Artery Atherosclerotic Etiology and Recurrent Stroke in TIA Patients. Cerebrovascular Diseases, 2012, 33, 150-158.	1.7	36
245	Role of the MMP9 Gene in Hemorrhagic Transformations After Tissue-Type Plasminogen Activator Treatment in Stroke Patients. Stroke, 2012, 43, 1398-1400.	2.0	13
246	A new method for focal transient cerebral ischaemia by distal compression of the middle cerebral artery. Neuropathology and Applied Neurobiology, 2012, 38, 617-627.	3.2	38
247	Citicoline in preâ€clinical animal models of stroke: a metaâ€analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. Journal of Neurochemistry, 2012, 123, 217-225.	3.9	29
248	<i>IL1B</i> and <i>VWF</i> Variants Are Associated With Fibrinolytic Early Recanalization in Patients With Ischemic Stroke. Stroke, 2012, 43, 2659-2665.	2.0	28
249	A predictive clinical–genetic model of tissue plasminogen activator response in acute ischemic stroke. Annals of Neurology, 2012, 72, 716-729.	5.3	39
250	Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting. Atherosclerosis, 2012, 220, 532-536.	0.8	14
251	No association of ALOX5AP polymorphisms with risk of MRI-defined brain infarcts. Neurobiology of Aging, 2012, 33, 629.e1-629.e3.	3.1	7
252	Evidence for the efficacy of statins in animal stroke models: a metaâ€analysis. Journal of Neurochemistry, 2012, 122, 233-243.	3.9	70

Joan Montaner

#	Article	IF	CITATIONS
253	<i>TTC7B</i> Emerges as a Novel Risk Factor for Ischemic Stroke Through the Convergence of Several Genome-Wide Approaches. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1061-1072.	4.3	86
254	Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: The S100B/RAGE pathway. Journal of Proteomics, 2012, 75, 4758-4765.	2.4	68
255	Plasma β-Amyloid Levels in Cerebral Amyloid Angiopathy-Associated Hemorrhagic Stroke. Neurodegenerative Diseases, 2012, 10, 320-323.	1.4	41
256	Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2012, 11, 951-962.	10.2	445
257	VAP-1/SSAO Plasma Activity and Brain Expression in Human Hemorrhagic Stroke. Cerebrovascular Diseases, 2012, 33, 55-63.	1.7	41
258	Intra-Arterial Bone Marrow Mononuclear Cells in Ischemic Stroke. Stroke, 2012, 43, 2242-2244.	2.0	208
259	MMPâ€2/MMPâ€9 Plasma Level and Brain Expression in Cerebral Amyloid Angiopathyâ€Associated Hemorrhagic Stroke. Brain Pathology, 2012, 22, 133-141.	4.1	73
260	Blood Glutathione S-Transferase-Ï€ as a Time Indicator of Stroke Onset. PLoS ONE, 2012, 7, e43830.	2.5	27
261	Brain Extracellular Fluid Protein Changes in Acute Stroke Patients. Journal of Proteome Research, 2011, 10, 1043-1051.	3.7	90
262	European Research Priorities for Intracerebral Haemorrhage. Cerebrovascular Diseases, 2011, 32, 409-419.	1.7	45
263	ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy. Neurobiology of Aging, 2011, 32, 551.e13-551.e22.	3.1	22
264	A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis, 2011, 216, 205-211.	0.8	103
265	Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease. Atherosclerosis, 2011, 218, 181-187.	0.8	24
266	Brain Perihematoma Genomic Profile Following Spontaneous Human Intracerebral Hemorrhage. PLoS ONE, 2011, 6, e16750.	2.5	60
267	Genetics of intracerebral haemorrhage: a tsunami effect of APOE ɛ2 genotype on brain bleeding size?. Lancet Neurology, The, 2011, 10, 673-675.	10.2	15
268	Effects of acute post-treatment with dipyridamole in a rat model of focal cerebral ischemia. Brain Research, 2011, 1373, 211-220.	2.2	24
269	Antibodies Preventing the Interaction of Tissue-Type Plasminogen Activator With N-Methyl- <scp>d</scp> -Aspartate Receptors Reduce Stroke Damages and Extend the Therapeutic Window of Thrombolysis. Stroke, 2011, 42, 2315-2322.	2.0	63
270	Ischemic Stroke Outcome and Early Infection: Its Deleterious Effect Seems to Operate Also among Tissue Plasminogen Activator-Treated Patients. European Neurology, 2011, 65, 82-87.	1.4	8

#	Article	IF	CITATIONS
271	The Proteome of Human Brain After Ischemic Stroke. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1105-1115.	1.7	43
272	Oxidative Stress After Thrombolysis-Induced Reperfusion in Human Stroke. Stroke, 2010, 41, 653-660.	2.0	83
273	Reperfusion Therapy for Acute Stroke Improves Outcome by Decreasing Neuroinflammation. Translational Stroke Research, 2010, 1, 261-267.	4.2	9
274	Matrix metalloproteinase-9 in fulminant hepatic failure. Hepatology, 2010, 51, 1475-1476.	7.3	5
275	Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Annals of Neurology, 2010, 68, 934-943.	5.3	241
276	Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. Journal of Neurochemistry, 2010, 112, 134-149.	3.9	118
277	Association of a Genetic Variant in the <i>ALOX5AP</i> with Higher Risk of Ischemic Stroke: A Case-Control, Meta-Analysis and Functional Study. Cerebrovascular Diseases, 2010, 29, 528-537.	1.7	54
278	Matrix Metalloproteinase 2 (MMP-2) Degrades Soluble Vasculotropic Amyloid-β E22Q and L34V Mutants, Delaying Their Toxicity for Human Brain Microvascular Endothelial Cells. Journal of Biological Chemistry, 2010, 285, 27144-27158.	3.4	43
279	Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke. Stroke, 2010, 41, 1528-1535.	2.0	66
280	The Association of the 4q25 Susceptibility Variant for Atrial Fibrillation With Stroke Is Limited to Stroke of Cardioembolic Etiology. Stroke, 2010, 41, 1850-1857.	2.0	76
281	Metalloproteinase and stroke infarct size: role for antiâ€inflammatory treatment?. Annals of the New York Academy of Sciences, 2010, 1207, 123-133.	3.8	133
282	Mobilization, endothelial differentiation and functional capacity of endothelial progenitor cells after ischemic stroke. Microvascular Research, 2010, 80, 317-323.	2.5	69
283	KCNK17 genetic variants in ischemic stroke. Atherosclerosis, 2010, 208, 203-209.	0.8	22
284	Stroke with polyvascular atherothrombotic disease. Atherosclerosis, 2010, 208, 587-592.	0.8	18
285	<i>CD40</i> -1C>T polymorphism (rs1883832) is associated with brain vessel reocclusion after fibrinolysis in ischemic stroke. Pharmacogenomics, 2010, 11, 763-772.	1.3	16
286	Blood Biomarkers in Cardioembolic Stroke. Current Cardiology Reviews, 2010, 6, 194-201.	1.5	16
287	Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA. Thrombosis and Haemostasis, 2009, 102, 759-764.	3.4	19
288	Statin use before and after acute ischemic stroke onset improves neurological outcome. Expert Review of Cardiovascular Therapy, 2009, 7, 1219-1230.	1.5	13

#	Article	IF	CITATIONS
289	Endogenous Activated Protein C Predicts Hemorrhagic Transformation and Mortality after Tissue Plasminogen Activator Treatment in Stroke Patients. Cerebrovascular Diseases, 2009, 28, 143-150.	1.7	23
290	Triflusal and Aspirin Have Different Effects on Inflammatory Biomarkers Measured in Patients with Acute Ischemic Stroke. Cerebrovascular Diseases, 2009, 28, 371-377.	1.7	3
291	Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain, 2009, 132, 2219-2230.	7.6	36
292	C-Reactive Protein Gene C1444T Polymorphism and Risk of Recurrent Ischemic Events in Patients with Symptomatic Intracranial Atherostenoses. Cerebrovascular Diseases, 2009, 28, 95-102.	1.7	22
293	Neuronal TIMPâ€1 release accompanies astrocytic MMPâ€9 secretion and enhances astrocyte proliferation induced by βâ€amyloid 25–35 fragment. Journal of Neuroscience Research, 2009, 87, 2115-2125.	2.9	34
294	Matrix Metalloproteinase-13 is Activated and is found in the Nucleus of Neural Cells after Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 398-410.	4.3	61
295	Interleukin-1β Augments Angiogenic Responses of Murine Endothelial Progenitor Cells <i>in Vitro</i> . Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 933-943.	4.3	66
296	Vascular MMP-9/TIMP-2 and Neuronal MMP-10 Up-Regulation in Human Brain after Stroke: A Combined Laser Microdissection and Protein Array Study. Journal of Proteome Research, 2009, 8, 3191-3197.	3.7	93
297	CADASIL management or what to do when there is little one can do. Expert Review of Neurotherapeutics, 2009, 9, 197-210.	2.8	20
298	Role of Endogenous Granulocyte-Macrophage Colony Stimulating Factor Following Stroke and Relationship to Neurological Outcome. Current Neurovascular Research, 2009, 6, 246-251.	1.1	18
299	Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases. Intensive Care Medicine, 2008, 34, 1384-1392.	8.2	77
300	Do Bubble Characteristics Affect Recanalization in Stroke Patients Treated with Microbubble-Enhanced Sonothrombolysis?. Ultrasound in Medicine and Biology, 2008, 34, 1573-1577.	1.5	53
301	Design of a Prospective Multi-National CLOTBUST Collaboration on Reperfusion Therapies for Stroke. International Journal of Stroke, 2008, 3, 66-72.	5.9	36
302	Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. Journal of Leukocyte Biology, 2008, 84, 207-214.	3.3	118
303	Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers. Stroke, 2008, 39, 2280-2287.	2.0	264
304	Progression of Symptomatic Intracranial Large Artery Atherosclerosis Is Associated With a Proinflammatory State and Impaired Fibrinolysis. Stroke, 2008, 39, 1456-1463.	2.0	89
305	Cholesterol Measured Before Stroke Thrombolysis Is Not Associated With Tissue Plasminogen Activator–Related Hemorrhagic Transformation. Stroke, 2008, 39, e6.	2.0	14
306	MMP-9–Positive Neutrophil Infiltration Is Associated to Blood–Brain Barrier Breakdown and Basal Lamina Type IV Collagen Degradation During Hemorrhagic Transformation After Human Ischemic Stroke. Stroke, 2008, 39, 1121-1126.	2.0	466

#	Article	IF	CITATIONS
307	Genetics of stroke: a review of recent advances. Expert Review of Molecular Diagnostics, 2008, 8, 495-513.	3.1	49
308	Fas System Activation in Perihematomal Areas After Spontaneous Intracerebral Hemorrhage. Stroke, 2008, 39, 1730-1734.	2.0	39
309	Response to Letter by Poppe et al. Stroke, 2008, 39, .	2.0	0
310	Absence of Usefulness of ABCD Score in the Early Risk of Stroke of Transient Ischemic Attack Patients. Stroke, 2007, 38, 855-856.	2.0	36
311	Speed of tPA-Induced Clot Lysis Predicts DWI Lesion Evolution in Acute Stroke. Stroke, 2007, 38, 955-960.	2.0	46
312	Prior Statin Use May Be Associated With Improved Stroke Outcome After Tissue Plasminogen Activator. Stroke, 2007, 38, 1076-1078.	2.0	75
313	Elevated Serum S100B Levels Indicate a Higher Risk of Hemorrhagic Transformation After Thrombolytic Therapy in Acute Stroke. Stroke, 2007, 38, 2491-2495.	2.0	124
314	Patterns and Predictors of Early Risk of Recurrence After Transient Ischemic Attack With Respect to Etiologic Subtypes. Stroke, 2007, 38, 3225-3229.	2.0	204
315	The association of the Â1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica, 2007, 92, 513-518.	3.5	38
316	Ubiquitin Fusion Degradation Protein 1 as a Blood Marker for the Early Diagnosis of Ischemic Stroke. Biomarker Insights, 2007, 2, 117727190700200.	2.5	10
317	Astrocytic Induction of Matrix Metalloproteinase-9 and Edema in Brain Hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 460-468.	4.3	145
318	Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis, 2006, 187, 161-169.	0.8	89
319	Poststroke C-Reactive Protein Is a Powerful Prognostic Tool Among Candidates for Thrombolysis. Stroke, 2006, 37, 1205-1210.	2.0	90
320	Temporal Profile of Recanalization After Intravenous Tissue Plasminogen Activator. Stroke, 2006, 37, 1000-1004.	2.0	119
321	ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neuroscience Letters, 2006, 398, 167-171.	2.1	23
322	Response to Letter by Topakian et al. Stroke, 2006, 37, 2455-2456.	2.0	3
323	Comparison of the impact of atrial fibrillation on the risk of early death after stroke in women versus men. Journal of Neurology, 2006, 253, 1484-1489.	3.6	31
324	Pretreatment Hemostatic Markers of Symptomatic Intracerebral Hemorrhage in Patients Treated With Tissue Plasminogen Activator. Stroke, 2006, 37, 996-999.	2.0	54

#	Article	IF	CITATIONS
325	Increased Brain Expression of Matrix Metalloproteinase-9 After Ischemic and Hemorrhagic Human Stroke, 2006, 37, 1399-1406.	2.0	382
326	Reduction of Tissue Plasminogen Activator-Induced Matrix Metalloproteinase-9 by Simvastatin in Astrocytes. Stroke, 2006, 37, 1910-1912.	2.0	60
327	Tandem Internal Carotid Artery/Middle Cerebral Artery Occlusion. Stroke, 2006, 37, 2301-2305.	2.0	350
328	Plasma S100B Level After Acute Spontaneous Intracerebral Hemorrhage. Stroke, 2006, 37, 2837-2839.	2.0	58
329	Role of Fibrinogen Levels and Factor XIII V34L Polymorphism in Thrombolytic Therapy in Stroke Patients. Stroke, 2006, 37, 2288-2293.	2.0	54
330	Microbubble Administration Accelerates Clot Lysis During Continuous 2-MHz Ultrasound Monitoring in Stroke Patients Treated With Intravenous Tissue Plasminogen Activator. Stroke, 2006, 37, 425-429.	2.0	431
331	Stroke Biomarkers: Can They Help Us to Guide Stroke Thrombolysis?. Drug News and Perspectives, 2006, 19, 523.	1.5	22
332	VEGF-Induced BBB Permeability is Associated with an MMP-9 Activity Increase in Cerebral ischemia: Both Effects Decreased by ANG-1. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 1491-1504.	4.3	172
333	A Matrix Metalloproteinase Protein Array Reveals a Strong Relation Between MMP-9 and MMP-13 With Diffusion-Weighted Image Lesion Increase in Human Stroke. Stroke, 2005, 36, 1415-1420.	2.0	146
334	Tissue Plasminogen Activator Promotes Matrix Metalloproteinase-9 Upregulation After Focal Cerebral Ischemia. Stroke, 2005, 36, 1954-1959.	2.0	215
335	Treatment with statins in the acute phase of ischemic stroke. Expert Review of Neurotherapeutics, 2005, 5, 211-221.	2.8	21
336	Acute Hyperglycemia State Is Associated With Lower tPA-Induced Recanalization Rates in Stroke Patients. Stroke, 2005, 36, 1705-1709.	2.0	198
337	Angiogenesis in Symptomatic Intracranial Atherosclerosis. Stroke, 2005, 36, 92-97.	2.0	52
338	Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using Multimodal Transcranial Doppler/MRI Selection Protocol. Stroke, 2005, 36, 602-606.	2.0	128
339	Silent Myocardial Ischemia in Patients With Symptomatic Intracranial Atherosclerosis. Stroke, 2005, 36, 1201-1206.	2.0	46
340	Predictors of Early Arterial Reocclusion After Tissue Plasminogen Activator-Induced Recanalization in Acute Ischemic Stroke. Stroke, 2005, 36, 1452-1456.	2.0	199
341	A panel of biomarkers may successfully predict acute stroke diagnosis. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S117-S117.	4.3	2
342	Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thrombosis and Haemostasis, 2004, 91, 1146-1151.	3.4	86

#	Article	IF	CITATIONS
343	Ultrasound-Enhanced Systemic Thrombolysis for Acute Ischemic Stroke. New England Journal of Medicine, 2004, 351, 2170-2178.	27.0	1,006
344	Differential Pattern of Tissue Plasminogen Activator–Induced Proximal Middle Cerebral Artery Recanalization Among Stroke Subtypes. Stroke, 2004, 35, 486-490.	2.0	178
345	Temporal Profile of Matrix Metalloproteinases and Their Inhibitors After Spontaneous Intracerebral Hemorrhage. Stroke, 2004, 35, 1316-1322.	2.0	199
346	Admission Fibrinolytic Profile Is Associated With Symptomatic Hemorrhagic Transformation in Stroke Patients Treated With Tissue Plasminogen Activator. Stroke, 2004, 35, 2123-2127.	2.0	111
347	Higher Risk of Further Vascular Events Among Transient Ischemic Attack Patients With Diffusion-Weighted Imaging Acute Ischemic Lesions. Stroke, 2004, 35, 2313-2319.	2.0	210
348	Impact of Admission Hyperglycemia on Stroke Outcome After Thrombolysis. Stroke, 2004, 35, 2493-2498.	2.0	138
349	Plasmatic Level of Neuroinflammatory Markers Predict the Extent of Diffusion-Weighted Image Lesions in Hyperacute Stroke. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 1403-1407.	4.3	116
350	Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke. Circulation, 2003, 107, 598-603.	1.6	494
351	C-Reactive Protein Predicts Further Ischemic Events in First-Ever Transient Ischemic Attack or Stroke Patients With Intracranial Large-Artery Occlusive Disease. Stroke, 2003, 34, 2463-2468.	2.0	171
352	Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic Stroke. Stroke, 2003, 34, 1038-1040.	2.0	96
353	Effects of Admission Hyperglycemia on Stroke Outcome in Reperfused Tissue Plasminogen Activator–Treated Patients. Stroke, 2003, 34, 1235-1240.	2.0	235
354	Editorial Comment—Cooling Matrix Metalloproteinases to Improve Thrombolysis in Acute Ischemic Stroke. Stroke, 2003, 34, 2171-2172.	2.0	6
355	Safety Profile of Tissue Plasminogen Activator Treatment Among Stroke Patients Carrying a Common Polymorphism (C-1562T) in the Promoter Region of the Matrix Metalloproteinase-9 Gene. Stroke, 2003, 34, 2851-2855.	2.0	60
356	Matrix metalloproteinase—9 concentration after spontaneous intracerebral hemorrhage. Journal of Neurosurgery, 2003, 99, 65-70.	1.6	156
357	Prediction of Early Neurological Deterioration Using Diffusion- and Perfusion-Weighted Imaging in Hyperacute Middle Cerebral Artery Ischemic Stroke. Stroke, 2002, 33, 2197-2205.	2.0	160
358	Thrombolysis-Related Hemorrhagic Infarction. Stroke, 2002, 33, 1551-1556.	2.0	224
359	Time Course of Tissue Plasminogen Activator–Induced Recanalization in Acute Cardioembolic Stroke. Stroke, 2001, 32, 2821-2827.	2.0	152
360	Progression and Clinical Recurrence of Symptomatic Middle Cerebral Artery Stenosis. Stroke, 2001, 32, 2898-2904.	2.0	198

#	Article	IF	CITATIONS
361	Matrix Metalloproteinase Expression After Human Cardioembolic Stroke. Stroke, 2001, 32, 1759-1766.	2.0	327
362	Timing of Spontaneous Recanalization and Risk of Hemorrhagic Transformation in Acute Cardioembolic Stroke. Stroke, 2001, 32, 1079-1084.	2.0	235
363	Impaired Cerebrovascular Reactivity as a Risk Marker for First-Ever Lacunar Infarction. Stroke, 1999, 30, 2296-2301.	2.0	116